Triple Negative Breast Cancer Metastatic Clinical Trials in Novara, Novara

Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel